Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
CTX-III reflects fibrosis resolution and is related to intervention and survival in CLD
January 4, 2025
The crosslinked type III collagen biomarker, CTX-III, reflects fibrosis resolution and is related to
intervention and survival in chronic liver disease
Introduction
Liver fibrosis progresses by deposing increasing amounts of crosslinked collagens in the extracellular matrix (ECM), destroying the liver parenchyma in the process. Treatments that hamper fibrosis could trigger the degradation of crosslinked fragments. A biomarker that measures the destruction of crosslinked collagen could open a window into the evolution of disease and the effectivity of
therapy. We hypothesize that circulating fragments of crosslinked collagen type III (CTX-III) can be detected and measured to reflect fibrinolysis, and thus biomark fibrosis resolution.
Poster
Conclusion
CTX-III is a biomarker engineered to detect enzymatically degraded crosslinked collagen type III. Its levels have been shown to increase after bariatric surgery, suggesting it is possible to measure systemic response to surgical intervention. Additionally, the CTX-III:PRO-C3 ratio detects a subpopulation of cirrhotic patients who respond to TIPS with significantly longer survival.
